(Q35909326)

11 August 2017

1 reference

title

Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma (English)

1 reference

11 August 2017

Sherif S Farag

1

1 reference

11 August 2017

Michael A Caligiuri

series ordinal

2

1 reference

11 August 2017

publication date

1 January 2004

1 reference

11 August 2017

published in

Advances in Pharmacology

1 reference

11 August 2017

volume

51

1 reference

11 August 2017

page(s)

295-318

1 reference

Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Role of IL12 as an anti-tumour agent: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Granulocyte-macrophage colony stimulating factor in autologous bone marrow transplantation: augmentation of graft versus tumor effect via antibody dependent cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

1 reference

7 January 2021

New directions in natural killer cell-based immunotherapy of human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Interleukin 15: biology and relevance to human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Ontogeny and expansion of human natural killer cells: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Interleukin-2 and interleukin-15: immunotherapy for cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Anti-myeloma activity of natural killer lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

In search of the 'missing self': MHC molecules and NK cell recognition

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Paired inhibitory and triggering NK cell receptors for HLA class I molecules.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

NK cell recognition of non-classical HLA class I molecules

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Recognition of virus-infected cells by natural killer cell clones is controlled by polymorphic target cell elements

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

A pilot study evaluating interleukin-2-activated hematopoietic stem cell transplantation for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Natural killer cells and their receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recogn

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Demonstration by class I gene transfer that reduced susceptibility of human cells to natural killer cell-mediated lysis is inversely correlated with HLA class I antigen expression

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Biology of natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Interleukin-12-induced cytotoxicity against syngeneic B cell lymphomas of SJL/J mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

Skin graft rejection by beta 2-microglobulin-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951013-X

7 January 2021

10.1016/S1054-3589(04)51013-X

Identifiers

DOI

0 references

1 reference